Slingshot Biosciences develops the world’s first on‑demand synthetic cell platform to produce off‑the‑shelf, cell‑like reagents that are stable, low‑cost, and targeted to a range of indications. The company leverages distributed manufacturing, engineering, and polymer chemistry to create cell and cell line mimics for diagnostics, controls, and biopharma applications. Slingshot has established commercial traction in controls and diagnostics and reports strong customer demand. The firm plans to accelerate commercialization and expand its adoptive cell therapy and therapeutics platform using the new financing. It is developing next‑generation adoptive cell therapy tools and additional therapeutic modalities and will further invest in functional cell programs for biopharma customers. The company highlights the broad market need for cell‑derived references, noting that 750 blood samples are tested every second in the U.S. and rely on such references. Slingshot Biosciences builds an on-demand synthetic cell platform to produce off‑the‑shelf, cell-like reagents for diagnostics, controls, and therapeutic applications. The company leverages distributed manufacturing, engineering, and polymer chemistry to create stable, low-cost reagents intended to reduce supply‑chain constraints and variability associated with donor‑sourced cell materials. Slingshot operated in stealth beginning in 2012 and launched its first suite of products in 2020. With the platform the company targets diagnostics (cell-derived references for testing) and next‑generation adoptive cell therapy tools and therapeutics. The firm plans to commercialize products across multiple verticals and to invest heavily in its broader adoptive cell therapy and therapeutics platform. Slingshot is based in Emeryville, Calif., and emphasizes scalability and accessibility of cell-derived products.

Total raised

$34M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2023